Mechanistic Insights Into Persistent Bacterial Cystitis as a Basis for Vaccine Development: A Narrative Review

키워드

참고문헌 (81)

1. Yang X, "Disease burden and long-term trends of urinary tract infections : a worldwide report", Front Public Health, 10, pp.888205~ (2022)
2. Dielubanza EJ, "Urinary tract infections in women", Med Clin North Am, 95, pp.27~41 (2011)
3. Timm MR, "Urinary tract infections : pathogenesis, host susceptibility and emerging therapeutics", Nat Rev Microbiol (2024)[DOI]
4. Wagenlehner F, "Social and economic burden of recurrent urinary tract infections and quality of life : a patient web-based study(GESPRIT)", Expert Rev Pharmacoecon Outcomes Res, 18, pp.107~117 (2018)
5. "National Hospital Ambulatory Medical Care Survey: 2018 emergency department summary tables"[URL]
6. Hunstad DA, "Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli", Annu Rev Microbiol, 64, pp.203~221 (2010)
7. Aslam S, "Recurrent urinary tract infections in adult women", JAMA, 323, pp.658~659 (2020)
8. Brauner A, "Urinary Escherichia coli causing recurrent infections--a prospective follow-up of biochemical phenotypes", Clin Nephrol, 38, pp.318~323 (1992)
9. Foxman B, "Epidemiology of urinary tract infections : transmission and risk factors, incidence, and costs", Infect Dis Clin North Am, 17, pp.227~241 (2003)
10. Luo Y, "Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection", J Clin Microbiol, 50, pp.4002~4007 (2012)
11. Anderson GG, "Intracellular bacterial biofilm-like pods in urinary tract infections", Science, 301, pp.105~107 (2003)
12. Rosen DA, "Detection of intracellular bacterial communities in human urinary tract infection", PLoS Med, 4, pp.e329~ (2007)
13. Hannan TJ, "Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection", FEMS Microbiol Rev, 36, pp.616~648 (2012)
14. Flores-Mireles AL, "Urinary tract infections : epidemiology, mechanisms of infection and treatment options", Nature Reviews Microbiology, 13, pp.269~284 (2015)
15. Whelan S, "Uropathogenic Escherichia coli(UPEC)-associated urinary tract infections : the molecular basis for challenges to effective treatment", Microorganisms, 11, pp.2169~ (2023)
16. Naskar M, "α-Hemolysin promotes uropathogenic E. coli persistence in bladder epithelial cells via abrogating bacteria-harboring lysosome acidification", PLoS Pathog, 19, pp.e1011388~ (2023)
17. Bien J, "Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage", Int J Nephrol, 2012, pp.681473~ (2012)
18. Naskar M, "A dynamic interplay of innate immune responses during urinary tract infection", Immune Netw, 24, pp.e31~ (2024)
19. Zhou G, "Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli : evidence from in vitro FimH binding", J Cell Sci, 114, pp.4095~4103 (2001)
20. Hooton TM, "Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults : 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.625~663 (2010)
21. Stamm WE, "Diagnosis of coliform infection in acutely dysuric women", New Engl J Med, 307, pp.463~468 (1982)
22. Connell I, "Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract", Proc Natl Acad Sci U S A, 93, pp.9827~9832 (1996)
23. Korhonen TK, "Localization of binding sites for purified Escherichia coli P fimbriae in the human kidney", Infect Immun, 54, pp.328~332 (1986)
24. Song J, "TLR4-mediated expulsion of bacteria from infected bladder epithelial cells", Proc Natl Acad Sci U S A, 106, pp.14966~14971 (2009)
25. Bishop BL, "Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells", Nat Med, 13, pp.625~630 (2007)
26. Mysorekar IU, "Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract", Proc Natl Acad Sci U S A, 103, pp.14170~14175 (2006)
27. Kerrn MB, "Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice", J Antimicrob Chemother, 55, pp.383~386 (2005)
28. Choi N, "A shared mechanism of multidrug resistance in laboratory-evolved uropathogenic Escherichia coli", Virulence, 15, pp.2367648~ (2024)
29. Mulvey MA, "Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection", Infect Immun, 69, pp.4572~4579 (2001)
30. De Nisco NJ, "Direct detection of tissue-resident bacteria and chronic inflammation in the bladder wall of postmenopausal women with recurrent urinary tract infection", J Mol Biol, 431, pp.4368~4379 (2019)
31. Eto DS, "Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli", Cell Microbiol, 8, pp.704~717 (2006)
32. Schreiber HL 4th, "Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections", Sci Transl Med, 9, pp.eaaf1283~ (2017)
33. Rippere-Lampe KE, "Mutation of the gene encoding cytotoxic necrotizing factor type 1(cnf(1))attenuates the virulence of uropathogenic Escherichia coli", Infect Immun, 69, pp.3954~3964 (2001)
34. Mobley HL, "Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells : role of hemolysin in some strains", Infect Immun, 58, pp.1281~1289 (1990)
35. O'Hanley P, "Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney : efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB", c mouse model of pyelonephritis, 1991, pp.59, 1153~1161
36. Nagy G, "Both alpha-haemolysin determinants contribute to full virulence of uropathogenic Escherichia coli strain 536", Microbes Infect, 8, pp.2006~2012 (2006)
37. Sandberg T, "Virulence of Escherichia coli in relation to host factors in women with symptomatic urinary tract infection", J Clin Microbiol, 26, pp.1471~1476 (1988)
38. Orskov I, "Aerobactin production of serotyped Escherichia coli from urinary tract infections", Med Microbiol Immunol, 177, pp.9~14 (1988)
39. O'Hanley P, "Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli", N Engl J Med, 313, pp.414~420 (1985)
40. Marrs CF, "Variations in 10 putative uropathogen virulence genes among urinary, faecal and peri-urethral Escherichia coli", J Med Microbiol, 51, pp.138~142 (2002)
41. Smith YC, "Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice", Infect Immun, 76, pp.2978~2990 (2008)
42. Nagamatsu K, "Dysregulation of Escherichia coli alpha-hemolysin expression alters the course of acute and persistent urinary tract infection", Proc Natl Acad Sci U S A, 112, pp.E871~E880 (2015)
43. Dhakal BK, "The UPEC pore-forming toxin alpha-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways", Cell Host Microbe, 11, pp.58~69 (2012)
44. Ristow LC, "Hemolysin of uropathogenic Escherichia coli : a cloak or a dagger?", Biochim Biophys Acta, 1858, pp.538~545 (2016)
45. van Meer G, "Membrane lipids : where they are and how they behave", Nat Rev Mol Cell Biol, 9, pp.112~124 (2008)
46. Powers ME, "ADAM10mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin", J Infect Dis, 206, pp.352~356 (2012)
47. Wankel B, "Sequential and compartmentalized action of Rabs, SNAREs, and MAL in the apical delivery of fusiform vesicles in urothelial umbrella cells", Mol Biol Cell, 27, pp.1621~1634 (2016)
48. Yates RM, "The kinetics of phagosome maturation as a function of phagosome", lysosome fusion and acquisition of hydrolytic activity, 2005, pp.6, 413~420
49. Tsang AW, "Altered membrane trafficking in activated bone marrow-derived macrophages", J Leukoc Biol, 68, pp.487~494 (2000)
50. -ATPase in vivo, "J Biol Chem", 2001, 24855~24861
51. Sun-Wada GH, "Direct recruitment of H+-ATPase from lysosomes for phagosomal acidification", J Cell Sci, 122, pp.2504~2513 (2009)
52. Harrison RE, "Phagosomes fuse with late endosomes and", or lysosomes by extension of membrane protrusions along microtubules : role of Rab7 and RILP, 2003, pp.23, 6494~6506
53. Deakin NO, "Paxillin comes of age", J Cell Sci, 121, pp.2435~2444 (2008)
54. Brown MC, "Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding", J Cell Biol, 135, pp.1109~1123 (1996)
55. Spano S, "A bacterial pathogen targets a host rab-family gtpase defense pathway with a GAP", Cell Host Microbe, 19, pp.216~226 (2016)
56. Fratti RA, "Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest", J Cell Biol, 154, pp.631~644 (2001)
57. D'Costa VM, "Salmonella disrupts host endocytic trafficking by SopD2-mediated inhibition of Rab7", Cell Rep, 12, pp.1508~1518 (2015)
58. Bumba L, "Calcium-driven folding of RTX domain beta-rolls ratchets translocation of RTX proteins through type I secretion ducts", Mol Cell, 62, pp.47~62 (2016)
59. Gerasimenko JV, "Calcium uptake via endocytosis with rapid release from acidifying endosomes", Curr Biol, 8, pp.1335~1338 (1998)
60. Nicaud JM, "Regulation of haemolysin synthesis in E. coli determined by HLY genes of human origin", Mol Gen Genet, 199, pp.111~116 (1985)
61. Chen S, "Dysregulated hemolysin liberates bacterial outer membrane vesicles for cytosolic lipopolysaccharide sensing", PLoS Pathog, 14, pp.e1007240~ (2018)
62. Huttner A, "Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection : a randomised, single-blind, placebo-controlled phase 1b trial", Lancet Infect Dis, 17, pp.528~537 (2017)
63. Frenck RW Jr, "Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial", Lancet Infect Dis, 19, pp.631~640 (2019)
64. Neutra MR, "Mucosal vaccines : the promise and the challenge", Nat Rev Immunol, 6, pp.148~158 (2006)
65. Lamm ME, "Interaction of antigens and antibodies at mucosal surfaces", Annu Rev Microbiol, 51, pp.311~340 (1997)
66. van Egmond M, "IgA and the IgA Fc receptor", Trends Immunol, 22, pp.205~211 (2001)
67. Black KP, "Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity", Clin Immunol Immunopathol, 81, pp.182~190 (1996)
68. Loubet P, "Alternative therapeutic options to antibiotics for the treatment of urinary tract infections", Front Microbiol, 11, pp.1509~ (2020)
69. Aziminia N, "Vaccines for the prevention of recurrent urinary tract infections : a systematic review", BJU Int, 123, pp.753~768 (2019)
70. Brodie A, "A retrospective study of immunotherapy treatment with Uro-Vaxom(OM-89(R))for prophylaxis of recurrent urinary tract infections", Curr Urol, 14, pp.130~134 (2020)
71. Nickel JC, "An effective sublingual vaccine, mv140, safely reduces risk of recurrent urinary tract infection in women", Pathogens, 12, pp.359~ (2023)
72. Cruz F, "Recurrent urinary tract infections : Uro-Vaxom®, a new alternative", Eur Urol Suppl, 8, pp.762~768 (2009)
73. Kovacic J, "Evaluation of MV140 in preventing recurrent urinary tract infections : a multicentre double-blind randomized controlled trial protocol", BJU Int, 133(Suppl 4), pp.37~43 (2024)
74. Lorenzo-Gomez MF, "Sublingual MV140 for prevention of recurrent urinary tract infections", NEJM Evid, 1, pp.EVIDx2200081~ (2022)
75. Eldridge GR, "Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections : results from a first-in-human phase 1 study", Hum Vaccin Immunother, 17, pp.1262~1270 (2021)
76. Wu J, "A highly polarized T(H)2 bladder response to infection promotes epithelial repair at the expense of preventing new infections", Nat Immunol, 21, pp.671~683 (2020)
77. Wu J, "Local induction of bladder Th1 responses to combat urinary tract infections", Proc Natl Acad Sci U S A, 118, pp.e2026461118~ (2021)
78. Suk G, "Stabilization of activated mast cells by ORAI1 inhibitor suppresses peanut-induced anaphylaxis and acute diarrhea", Pharmacol Res, 196, pp.106887~ (2023)
79. Konesan J, "The clinical trial outcomes of cranberry, D-Mannose and NSAIDs in the prevention or management of uncomplicated urinary tract infections in women : a systematic review", Pathogens, 11, pp.1471~ (2022)
80. Mydock-McGrane L, "Antivirulence C-Mannosides as antibiotic-sparing, oral therapeutics for urinary tract infections", J Med Chem, 59, pp.9390~9408 (2016)
81. Sibaud V, "Dermatological adverse events with taxane chemotherapy", Eur J Dermatol, 26, pp.427~443 (2016)

관련 논문AI추천